Journal of Clinical Oncology
Articles in this Issue
Modernizing injectable cancer care delivery: A telemedicine-supported home injection model for breast cancer care.
1581 Background: Among the growing population of premenopausal patients with breast cancer, years-long endocrine therapy o...
Determinants of leadership attainment among ASCO Leadership Development Program, 2009–2025.
9037 Background: Determinants of leadership attainment among participants in formal leadership development programs remain...
Glucose 6-phosphate dehydrogenase deficiency and skin cancer: A retrospective study assessing cutaneous malignancy risk.
e21576 Background: Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme within the pentose phosphate pathway (PPP) that p...
ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor–positive (ER+), HER2-negative (HER2−), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.
TPS1153 Background: Adjuvant ET is the standard of care (SOC) for treating ER+/HER2- eBC. Despite advances to optimize adj...
Development of a supportive care intervention for caregivers of head and neck cancer patients: A qualitative needs assessment.
e24107 Background: Caregivers of patients with head and neck cancer (HNC) play a vital role in patient care and recovery,...
Palliative care utilization in metastatic triple-negative breast cancer: A National Cancer Database analysis.
e24073 Background: Metastatic triple-negative breast cancer (TNBC) is associated with aggressive disease biology and poor...
Real-world eligibility for adjuvant CDK4/6 therapy in HR+/HER2− early breast cancer: A comparative analysis of monarchE and NATALEE criteria from a single-institution cohort.
e12532 Background: Adjuvant CDK4/6 inhibitors benefit selected HR+/HER2− early breast cancer (EBC), yet monarchE (high-ris...
Efficacy and safety of disitamab vedotin (DV) combined with trastuzumab, and tislelizumab versus chemotherapy (CAPOX) combined with trastuzumab ± pembrolizumab for patients with first-line HER2-high advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA): A randomized controlled phase 3 trial.
TPS4245 Background: Patients (pts) with HER2-high (defined as IHC 3+, or IHC 2+/FISH+ according to Chinese Society of Clin...
Real-world clinicogenomic comparison of early- and average-onset gastric cancer.
e16080 Background: In recent decades, there has been an unprecedented rise in gastric cancer among younger individuals, co...
Immune aging within the tumor microenvironment as a predictor of survival in non–small cell lung cancer.
8068 Background: Immune aging has been associated with survival outcomes in patients with lung adenocarcinoma (LUAD), but...
Epidemiology and healthcare burden of penile cancer in people living with HIV in the United States.
e17029 Background: HIV- positive patients are known to have worse outcomes with a 4-fold increased risk for death from pen...
DEB-TACE combined with apatinib and camrelizumab as second-line therapy for unresectable intrahepatic cholangiocarcinoma: A prospective, single-arm, phase II study.
4164 Background: This study aimed to evaluate the efficacy and safety of drug-eluting bead transarterial chemoembolization...
Association of prior SARS-CoV-2 infection with advanced cancer presentation in newly diagnosed solid tumors: A real-world data analysis.
10586 Background: Emerging evidence suggests that the impact of SARS-CoV-2 infection may extend beyond acute respiratory i...
Right-sided circulatory failure without pulmonary embolism in hospitalized cancer patients: National burden and inpatient outcomes.
e24033 Background: In hospitalized patients with cancer, acute right-sided circulatory failure is highly attributedto pulm...
Early detection of pancreatic ductal adenocarcinoma (PDAC) with a multiomic liquid biopsy.
4229 Background: Early diagnosis remains the major unmet challenge in pancreatic ductal adenocarcinoma (PDAC), which accou...
Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.
1107 Background: Bria-IMT is an allogeneic whole cell immunotherapy expressing tumor associated antigens and GM-CSF to sti...
First-in-human study of [ <sup>111</sup> In] XYIMSR-01 SPECT/CT, a novel carbonic anhydrase IX small molecule in patients with metastatic clear cell renal cell carcinoma.
TPS4635 Background: Clear cell renal cell carcinoma (ccRCC) accounts for approximately 75% of renal cancers and is charact...
<i>ESR1</i> hotspot–specific chemotherapy resistance patterns in metastatic breast cancer identified by ctDNA analysis.
e13009 Background: ESR 1 mutations are established drivers of endocrine resistance in ER+ metastatic b...
Genitourinary safety of SGLT2 inhibitors in patients with cancer and type 2 diabetes: A real-world analysis.
e23089 Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors are increasingly used for glycemic and cardiovascular...
Sequential or concurrent immunotherapy with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma.
2622 Background: First-line chemotherapy combined with immunotherapy (CT-IO), followed by selective locoregional radiother...
ISABELA: A phase 2 study of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
7562 Background: Combination therapies form the backbone of multiple myeloma (MM) care, and therapies targeting BCMA are n...
Improving post-discharge appointment coordination for hospitalized cancer patients utilizing inpatient patient service coordinators.
e13561 Background: Hospitalized cancer patients often require complex post-discharge care, including oncology follow-up, i...
The efficacy and safety of neoadjuvant toripalimab combined with temozolomide in resectable stage III melanoma: A prospective, single-center, phase 2 trial.
9562 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) have demonstrated efficacy in resectable cutaneous melano...
The role of tyrosine kinase inhibitors as a post-hematopoietic stem cell transplant maintenance therapy for pediatric acute leukemia.
e22003 Background: Hematopoietic stem cell transplantation (HSCT) is a critical component of care for pediatric acute leuk...
Assessing responses to UGN-102 across EORTC recurrence score groups in patients with recurrent low-grade intermediate-risk NMIBC (ENVISION trial).
4601 Background: The ENVISION phase 3 study (NCT05243550) treated patients with recurrent low-grade intermediate-risk non-...